Moon Surgical
Moon Surgical (previously MastOR SAS) is a Paris-based, early-stage medical device company, developing a surgical robot for laparoscopy assistance. It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund. The core technology is derived from joint research between the ISIR robotics lab at Sorbonne University and Professor Brice Gayet, a world-renowned surgeon and pioneer in minimally-invasive surgery.
Sector
Medical Devices
Strategies
MD Start & Capital
Status
Live
Website
www.moonsurgical.com
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Related News
Moon Surgical Expands Leadership Team to Accelerate Commercial Growth Across U.S. and Europe
Moon Surgical receives FDA clearance for ScoPilot™ on Maestro, industry's first AI-enhanced intraoperative capability, powered by NVIDIA Holoscan
Global debut in an ASC setting at Surgeon's Point Surgery Center for Moon Surgical's Maestro System
Moon Surgical appoints Chris Toth as Independent Board Member ahead of commercial acceleration
Enhanced data security and quality via ISO 27001:2022 and SOC 2 certifications enables Moon Surgical to deliver actionable insights to healthcare providers
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.